Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate for Obesity
NCT02754258Phase 3Unknown
- Sponsor
- Children's Hospital of Eastern Ontario
- Start
- Jan 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of methylphenidate hydrochloride extended-release chewable tablet in obesity, sponsored by Children's Hospital of Eastern Ontario. Primary endpoint: Change in Energy Intake at 60 days. Status: unknown.
02
Drugs
methylphenidate hydrochloride extended-release chewable tablet
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02754258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02754258.